ENANTA PHARMACEUTICALS INC (ENTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q4 '12: 41.7M Q1 '13: 68.8M Q2 '13: 33.5M Q3 '13: 32.6M Q4 '13: 32.1M Q1 '14: 5.1M Q2 '14: 6.1M Q3 '14: 46.5M Q4 '14: 47.7M Q1 '15: 124.3M Q2 '15: 179.6M Q3 '15: 149.1M Q4 '15: 160.9M Q1 '16: 131.8M Q2 '16: 87.5M Q3 '16: 89.8M Q4 '16: 88.3M Q1 '17: 50.2M Q2 '17: 46.2M Q3 '17: 39.7M Q4 '17: 102.8M Q1 '18: 130.5M Q2 '18: 165.6M Q3 '18: 215.3M Q4 '18: 206.6M Q1 '19: 238.4M Q2 '19: 234M Q3 '19: 221.1M Q4 '19: 205.2M Q1 '20: 187.9M Q2 '20: 175.9M Q3 '20: 150.2M Q4 '20: 122.5M Q1 '21: 101.6M Q2 '21: 94.2M Q3 '21: 97.1M Q4 '21: 97.1M Q1 '22: 93M Q2 '22: 91.6M Q3 '22: 89.4M Q4 '22: 86.2M Q1 '23: 82.1M Q2 '23: 81.2M Q3 '23: 80.6M Q4 '23: 79.2M Q1 '24: 73.6M Q2 '24: 72.9M Q3 '24: 72M Q4 '24: 67.6M Q1 '25: 66.6M Q2 '25: 64.5M Q3 '25: 64.8M Q4 '25: 65.3M Q1 '26: 67M Q2 '26: 69.2M Q3 '26: 65.3M Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '13: 9M Q1 '14: -18.3M Q2 '14: -19.5M Q3 '14: 19.6M Q4 '14: 19M Q1 '15: 94.7M Q2 '15: 148.3M Q3 '15: 115.1M Q4 '15: 124.1M Q1 '16: 89.5M Q2 '16: 40.4M Q3 '16: 37.6M Q4 '16: 30.8M Q1 '17: -11.8M Q2 '17: -20.7M Q3 '17: -32.8M Q4 '18: 88.3M Q1 '19: 101.8M Q2 '19: 83.6M Q3 '19: 64.8M Q4 '19: 36.7M Q1 '20: 21.8M Q2 '20: 11.2M Q3 '20: -15.4M Q4 '20: -41.6M Q1 '21: -66.8M Q2 '21: -84.6M Q3 '21: -95.6M Q4 '21: -109.6M Q1 '22: -127.7M Q2 '22: -131.8M Q3 '22: -130.5M Q4 '22: -123.8M Q1 '23: -123.4M Q2 '23: -129.1M Q3 '23: -133.2M Q4 '23: -137.2M Q1 '24: -142.1M Q2 '24: -135.4M Q3 '24: -122.9M Q4 '24: -121.7M Q1 '25: -110.3M Q2 '25: -102.1M Q3 '25: -96.8M Q4 '25: -85.3M Q1 '26: -73.1M Q2 '26: -60.4M Q3 '26: -58.7M Q1 '15 Q3 '16 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25 Q3 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '12: 21.4M Q1 '13: 46.5M Q2 '13: 10.7M Q3 '13: 10M Q4 '13: 9.6M Q1 '14: -17.7M Q2 '14: -19.2M Q3 '14: 35M Q4 '14: 34.4M Q1 '15: 81.8M Q2 '15: 115.8M Q3 '15: 68.1M Q4 '15: 79M Q1 '16: 63.2M Q2 '16: 32.8M Q3 '16: 29.3M Q4 '16: 21.7M Q1 '17: -9.5M Q2 '17: -13.2M Q3 '17: -20.6M Q4 '17: 17.7M Q1 '18: 34.4M Q2 '18: 52.3M Q3 '18: 81M Q4 '18: 72M Q1 '19: 86.3M Q2 '19: 77.9M Q3 '19: 64.6M Q4 '19: 46.4M Q1 '20: 33.8M Q2 '20: 23.7M Q3 '20: 2.4M Q4 '20: -36.2M Q1 '21: -57.9M Q2 '21: -74M Q3 '21: -83.7M Q4 '21: -79M Q1 '22: -100.8M Q2 '22: -112.3M Q3 '22: -120M Q4 '22: -121.8M Q1 '23: -120.6M Q2 '23: -124.7M Q3 '23: -132.1M Q4 '23: -133.8M Q1 '24: -138.2M Q2 '24: -131.7M Q3 '24: -115.3M Q4 '24: -116M Q1 '25: -104.9M Q2 '25: -96.4M Q3 '25: -92M Q4 '25: -81.9M Q1 '26: -71.5M Q2 '26: -62M Q3 '26: -63.2M Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q4 '13: 10.7M Q1 '14: -4.3M Q2 '14: -18.4M Q3 '14: 22.6M Q4 '14: 20.2M Q1 '15: 20.4M Q2 '15: 123.4M Q3 '15: 74.1M Q4 '15: 76.7M Q1 '16: 112.3M Q2 '16: 23.5M Q3 '16: 35.6M Q4 '16: 35.8M Q1 '17: 9M Q2 '17: -4.1M Q3 '17: -6.8M Q4 '17: 52.7M Q1 '18: 53.9M Q2 '18: 49.3M Q3 '18: 58.2M Q4 '18: 29.2M Q1 '19: 55.1M Q2 '19: 92.7M Q3 '19: 91.2M Q4 '19: 71.4M Q1 '20: 53.5M Q2 '20: 38.1M Q3 '20: 31.1M Q4 '20: 7.1M Q1 '21: -20.2M Q2 '21: -39.4M Q3 '21: -64.4M Q4 '21: -70M Q1 '22: -68.4M Q2 '22: -90.2M Q3 '22: -90.3M Q4 '22: -84.8M Q1 '23: -107.2M Q2 '23: -94.6M Q3 '23: -97.1M Q4 '23: -103.2M Q1 '24: -92.5M Q2 '24: -107.3M Q3 '24: -90M Q4 '24: -78.8M Q1 '25: -70.6M Q2 '25: -55.5M Q3 '25: -23.2M Q4 '25: -19.3M Q1 '26: -14.2M Q2 '26: -7.8M Q3 '26: -35.3M Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q4 '13: 10M Q1 '14: -4.9M Q2 '14: -18.8M Q3 '14: 21.9M Q4 '14: 19.2M Q1 '15: 19.2M Q2 '15: 122.2M Q3 '15: 72.9M Q4 '15: 74.3M Q1 '16: 108M Q2 '16: 17.8M Q3 '16: 29.7M Q4 '16: 31.1M Q1 '17: 5.5M Q2 '17: -6.7M Q3 '17: -9.5M Q4 '17: 50.1M Q1 '18: 51.9M Q2 '18: 47.1M Q3 '18: 55.6M Q4 '18: 26.2M Q1 '19: 52.2M Q2 '19: 88.1M Q3 '19: 85.5M Q4 '19: 66M Q1 '20: 48M Q2 '20: 34.7M Q3 '20: 29.7M Q4 '20: 5.6M Q1 '21: -21.3M Q2 '21: -40.3M Q3 '21: -65.5M Q4 '21: -70.7M Q1 '22: -69.3M Q2 '22: -91M Q3 '22: -91M Q4 '22: -86.9M Q1 '23: -112.1M Q2 '23: -101.8M Q3 '23: -106.2M Q4 '23: -112.2M Q1 '24: -99.2M Q2 '24: -113.3M Q3 '24: -100.3M Q4 '24: -96.7M Q1 '25: -96.5M Q2 '25: -82.2M Q3 '25: -43.6M Q4 '25: -32.2M Q1 '26: -18.5M Q2 '26: -9.6M Q3 '26: -36.9M Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 10M 20M 30M Q2 '12: 2.5M Q3 '12: 1.1M Q1 '13: 2.6M Q2 '13: 2.2M Q3 '13: 17.8M Q1 '14: 17.9M Q2 '14: 18.4M Q3 '14: 19.2M Q1 '15: 19.3M Q2 '15: 19.3M Q3 '15: 19.3M Q1 '16: 19.3M Q2 '16: 18.9M Q3 '16: 19M Q1 '17: 19M Q2 '17: 19M Q3 '17: 19.1M Q1 '18: 19.9M Q2 '18: 20.6M Q3 '18: 21M Q1 '19: 20.8M Q2 '19: 21.1M Q3 '19: 21.1M Q1 '20: 20.8M Q2 '20: 19.9M Q3 '20: 20M Q1 '21: 20.1M Q2 '21: 20.2M Q3 '21: 20.2M Q1 '22: 20.4M Q2 '22: 20.6M Q3 '22: 20.7M Q1 '23: 20.8M Q2 '23: 21M Q3 '23: 21.1M Q1 '24: 21.1M Q2 '24: 21.2M Q3 '24: 21.2M Q1 '25: 21.2M Q2 '25: 21.4M Q3 '25: 21.4M Q1 '26: 28.7M Q2 '26: 29M Q3 '26: 29.1M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '14: -3.06 Q2 '14: -1.06 Q3 '14: 1.78 Q4 '14: 1.76 Q1 '15: 4.24 Q2 '15: 6.01 Q3 '15: 3.53 Q4 '15: 4.09 Q1 '16: 3.27 Q2 '16: 1.69 Q3 '16: 1.50 Q4 '16: 1.12 Q1 '17: -0.50 Q2 '17: -0.69 Q3 '17: -1.07 Q4 '17: 0.88 Q1 '18: 1.73 Q2 '18: 2.62 Q3 '18: 4.03 Q4 '18: 3.47 Q1 '19: 4.13 Q2 '19: 3.72 Q3 '19: 3.08 Q4 '19: 2.22 Q1 '20: 1.62 Q2 '20: 1.12 Q3 '20: 0.08 Q4 '20: -1.82 Q1 '21: -2.88 Q2 '21: -3.67 Q3 '21: -4.15 Q4 '21: -3.91 Q1 '22: -4.98 Q2 '22: -5.52 Q3 '22: -5.86 Q4 '22: -5.91 Q1 '23: -5.82 Q2 '23: -5.98 Q3 '23: -6.31 Q4 '23: -6.37 Q1 '24: -6.56 Q2 '24: -6.24 Q3 '24: -5.45 Q4 '24: -5.48 Q1 '25: -4.95 Q2 '25: -4.54 Q3 '25: -4.32 Q4 '25: -3.84 Q1 '26: -3.21 Q2 '26: -2.60 Q3 '26: -2.42 Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.